Thyroid

Publications

• Sugg SL, Zheng L, Ezzat S, Rosen IB, Freeman JL, Asa SL. Ret/PTC-1,-2,-3 oncogene rearrangements in human thyroid carcinoma: implications for metastatic potential? Journal of Clinical Endocrinology and Metabolism (1996 Sep) 81:3360-5.
• Weigel RJ (1996). Advances in the diagnosis and management of thyroid cancers. Current Opinion in Oncology 8:37-43.
• Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S. Asa SL. ErbB-2 Cytoplasmic staining but not mRNA levels correlate with differentiation in human thyroid neoplasm. Clinical Endocrinology, 1998;49:629-637.
• Sugg SL, Zheng L. Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple ret/PTC gene rearrangements in multifocal papillary thyroid neoplasia. Journal of Clinical Endocrinology and Metabolism, (1998 Nov) 83(11):4116-22.
• Carmeci C, Jeffrey RB, McDougall IR, Nowels KW, Weigel RJ (1998). Ultrasound-guided fine needle aspiration biopsy of thyroid masses. Thyroid 8:283-289.
• Soravia C, Sugg SL, Berk T, Mitri A, Cheng H, Gallinger S, Cohen Z, Asa SL, Bapat BV. Familial adenomatous polyposis coli associated thyroid cancer: a clinical, pathological, and molecular genetic study. American Journal of Pathology, 1999;54:127-135.
• Sugg SL, Zheng, Freeman JL, Rosen IB, Ezzat S, Asa SL. Oncogene profile of papillary thyroid carcinoma. Surgery, 1999;125:46-52.
• Durski JM, Weigel RJ and McDougall IR (2000). Recombinant Human Thyrotropin (rhTSH) in the Management of Differentiated Thyroid Cancer. Nuclear Medicine Communications 21:521-528.
• Desai D, Jeffrey RB, McDougall IR and Weigel RJ (2001). Intraoperative Ultrasonography for Localization of Recurrent Thyroid Cancer. Surgery 129:498-500.
• Desai D, McPherson LA, Higgins JPT and Weigel RJ (2001) Genetic Analysis of a Papillary Thyroid Carcinoma in a Patient with MEN1. Annals of Surgical Oncology 8:342-6.
• McDougall IR and Weigel RJ (2001). Recombinant Human Thyrotropin in the Management of Thyroid Cancer. Current Opinion in Oncology 13:39-43.
• Karwowski JK, Jeffrey RB, McDougall IR, Weigel RJ (2002). Intraoperative ultrasonograpy improves identification of recurrent thyroid cancer. Surgery 132:924-9.
• Karwowski JK, Nowels KW, McDougall IR, Weigel RJ (2002). Needle Track Seeding of Papillary Thyroid Carcinoma from Fine Needle Aspiration Biopsy. Acta Cytologica 46:591-595.
• Clark OH and Lal G. Novel method for control of mediastinal bleeding during thyroidectomy for substernal goiter. J Am Coll Surg 196(5):818-20, May 2003
• Lal G, Brennan T, Hambleton J and Clark OH. Coagulopathy, marantic endocarditis and cerebrovascular accidents as paraneoplastic features in Medullary thyroid cancer. Thyroid 13(6): 601-5, June 2003.
• Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey RB (2003). Common and uncommon sonographic features of papillary thyroid carcinoma. Journal of Ultrasound in Medicine 22:1083-90.
• Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? Thyroid. 15(6):569-74, June 2005.
• Kim W, Bartel T, Juweid M, Lal G, Graham M Renal cyst uptake following I-131 treatment for thyroid cancer. Thyroid 16(12):1315-6, December 2006
• Lal G, Padmanabha L, Nicholson R, Smith BJ, Howe JR, O’Dorisio MS, Domann FE. RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinomas. Cancer 107(12):2752-9, December 2006.
• Lal, G., Padmanabha, L., Smith, B., Nicholson, R., Howe, J.R., O’Dorisio, M.S., Domann, F.E, (2006) RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma. Cancer 107: 2752-9.
• Weigel, RJ and McDougall, IR (2006). The Role of Radioactive Iodine in the Treatment of Well-differentiated Thyroid Cancer. Surgical Oncology Clinics of North America 15:625-38.

Book Chapters

• Lal G and Clark OH. Endocrine Surgery. In: Basic and Clinical Endocrinology 8th edition. Greenspan F and Gardner D (Editors).McGraw-Hill Companies. In press
• Maurice M and Lal G. Thyroidectomy Operative Anatomy 3rd Edition Editor: Scott-Conner C. Lippincott-Williams and Wilkins. In preparation
• Kaplan EL, Sugg SL, Costa E Jr. Thyroid Disease Manager, Surgery of the Thyroid Gland, Chapter 21, May 1, 1999. www.thyroidmanager.org/thyroidbook.htm.
• Costa EE, Sugg SL, Kaplan EL. Hyperthyroidism. In Surgical Endocrinology, Doherty, GM, Skogseid, B (eds), Lippincott Williams & Wilkins, Philadelphia, PA 21-36, 2001.
• Kaplan EL, Sugg SL. Surgery of the Thyroid Gland. Chapter 110, Endocrinology, 4th Edition. DeGroot LJ and Jameson JL Eds., WB Saunders Co., Philadelphia 1567-1585, 2001.
• Weigel RJ.(2001) Thyroid In: Surgery: Scientific Basis and Current Evidence, pp879-896, JA Norton, RR Bollinger, AE Chang, SF Lowry, SJ Mulvihill, HI Pass and RW Thompson (eds.). Springer-Verlag, New York.
• Lal G and Clark OH. Thyroiditis. In: Textbook of Endocrine Surgery 2nd Edition. Clark OH, Duh Q-Y and Kebebew E (Editors). Elsevier/Saunders 2005
• Weigel RJ.(2005) Thyroid In: Surgery: Scientific Basis and Current Evidence, Second Edition, JA Norton, RR Bollinger, AE Chang, SF Lowry, SJ Mulvihill, HI Pass and RW Thompson (eds.). Springer-Verlag, New York (In Press)

Presentations

• Howe J. R., “Medullary Thyroid Cancer”, 35th Annual Head and Neck and Neck Cancer and Reconstructive Surgery Course, Iowa City, IA, June 11, 2002
• Lal G and Clark OH., The axilla as a rare site of metastatic thyroid cancer with ominous implication, American Thyroid Association meeting, Los Angeles, California, 2002
• Weigel RJ, Speaker, Case for Total Thyroidectomy in Treatment of Well-Differentiated Thyroid Cancer American College of Surgeons Postgraduate Course, San Francisco, California, October 8, 2002
• Howe J. R., “The Genetic and Clinical Management of Medullary Thyroid Cancer” Brooklyn Surgical Society, December 4, 2003 Lal G., Familial Thyroid Cancer Grand Rounds, Department of Surgery, University of Iowa, 2003
• Lal G., Update Course: Optimal management of lymph node metastases in thyroid cancer, General Surgery, University of Iowa, 2004
• Lal G, Ituarte P, Kebebew E, Duh Q-Y, Clark OH, Should Total Thyroidectomy become the preferred procedure for surgical management of Graves ’ disease? International Association of Endocrine Surgeons meeting, Uppsala, Sweden, 2004
• Howe J.R., Radio Interview, “Thyroid Cancer”, KXIC, September 13, 2004.
• Weigel RJ. Speaker, Differentiated Thyroid Cancer, American College of Surgeons Postgraduate Course, New Orleans, Louisiana, October 11, 2004
• Lal G., ECM1 as a diagnostic marker in thyroid cancer , Endocrine-pathology-Radiology Conference, University of Iowa, 2005
• Lal G, Padmanabha L, Smith BJ, Howe J, O’Doriosio T, O’Dorisio S, ECM1 as a diagnostic marker in thyroid cancer, International Association of Endocrine Surgeons meeting, Durban, South Africa, 2005
• Lal G, Thyroid Cancer Genetics Grand Rounds, Department of Surgery, University of Iowa, 2006
• Weigel RJ. Speaker, Treatment of Well-Differentiated Thyroid Cancer, Department of Surgery Postgraduate Conference, University of Iowa, Iowa City, Iowa, November 9, 2006
• Lal G. “What’s new is Medullary thyroid cancer?”, Annual General Surgery Update Course, University of California, San Francisco, CA., 2007

Abstracts

• Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezat S, Asa SL. PTC/ret 1,2, & 3 expression in thyroid cancer. 10th International Conference on Endocrinology. June 1996, San Francisco.
• Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. PTC/ret 1,2, & 3 expression in thyroid cancer. Cold Spring Harbor Laboratory Symposium on Cancer Genetics & Tumor Suppressor Genes. August 1996.
• Sugg SL, Zheng, Hosal S, Rosen IB, Freeman JL, Ezzat S, Asa SL. Oncogene studies in human thyroid cancer. 4th International Conference on Neck & Neck Cancer. July 1996, Toronto.
• *Sugg SL, Ramyar L, Rosen IB, Ezzat S, Asa SL. Tumorigenesis in multifocal papillary thyroid carcinoma: Analysis by ret/PTC oncogene rearrangements. Surgical Forum, 1997.
• *Sugg SL, Ramyar L, Rosen IB, Freeman JL, Ezzat S, Asa SL. Ret/PTC oncogene rearrangements in multifocal papillary thyroid cancer: Evidence for discrete multicentric primary tumors. Annual Meeting of the Canadian Society of Surgical Oncology, 1997.
• *Sugg SL, Ramyar L. Rosen IB, Freeman JL, Ezzat S, Asa SL. Ret/PTC-1, 2, & 3 oncogene rearrangements are more prevalent in occult than in clinical papillary thyroid carcinoma. 79th Annual Meeting of The Endocrine Society, 1997.
• Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. The c-erbB-2 proto-oncogene in human thyroid cancer: DNA amplification, quantative mRNA expression, immunohistochemistry and mutational analysis. Society of Cancer Research, 1997.
• Xiang B, Du L, Hessner MJ, Jiang N, Kappes A, Shilyansky J, Wilson SD, Sugg SL. Comparison of metastatic vs. primary follicular thyroid carcinoma call lines by cDNA microarray. Presented at The Endocrine Society's 86th Annual Meeting. New Orleans, LA, June 16-19, 2004.
• Sugg SL, DM McAllister, RA Komorowski, MJ Hessner, J Shilyansky, TW Yen, SD Wilson. Use of Tissue Microarray to Evaluate Clinical Utility of Genes Overexpressed in a Metastatic Thyroid Cancer Cell Line. Presented at The Endocrine Society’s 87th Annual Meeting. San Diego, CA. June 2005.
• Sugg SL, McAllister DM, Komorowski, RA, Rowe J, Yen TW, Wilson SD, Shilyansky J. Targeting EphA2 inhibits invasiveness of thyroid cancer cells. American Association of Endocrine Surgeons 27th Annual Meeting, New York, NY, May 2006.
• Sugg SL, McAllister, DM, Komorowski RA, Rowe J, Yen TW, Wilson SD, Shilyansky J. Targeting EphA2 inhibits invasiveness of thyroid cancer cells. The Endocrine Society’s 2006 Annual Meeting “Endo 2006”, Boston, MA, June 2006.
• Tallar M, Yen TW, Kryzwda E, Wilson SD, Sugg SL. Incidental thyroid cancers are increasing-are they clinically significant? The 2nd Academic Surgical Congress, Phoenix, AZ, February 2007.